What is Bloom Burton’s Estimate for Cybin FY2025 Earnings?

Cybin Inc. (NYSE:CYBN) – Equities research analysts at Bloom Burton cut their FY2025 earnings per share estimates for Cybin in a research note issued on Tuesday, November 19th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of ($6.12) for the year, down from their previous forecast of ($4.46). The consensus estimate for Cybin’s current full-year earnings is ($3.37) per share. Bloom Burton also issued estimates for Cybin’s FY2026 earnings at ($6.51) EPS.

A number of other research firms have also weighed in on CYBN. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Cybin in a research report on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cybin in a research report on Wednesday, July 31st. Finally, Canaccord Genuity Group lowered their target price on Cybin from $96.00 to $86.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

Cybin Trading Down 3.5 %

NYSE CYBN opened at $9.80 on Friday. The company has a market cap of $195.92 million, a P/E ratio of -1.44 and a beta of 0.38. Cybin has a 1 year low of $6.50 and a 1 year high of $21.66. The business’s fifty day moving average price is $9.57.

Institutional Trading of Cybin

A number of hedge funds have recently bought and sold shares of CYBN. Sanctuary Advisors LLC acquired a new stake in shares of Cybin during the 2nd quarter worth approximately $36,000. PEAK6 Investments LLC acquired a new stake in Cybin during the first quarter worth $95,000. AdvisorShares Investments LLC increased its holdings in Cybin by 13.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock valued at $494,000 after buying an additional 220,403 shares during the period. AWM Investment Company Inc. acquired a new position in shares of Cybin in the 1st quarter valued at $930,000. Finally, Rosalind Advisors Inc. lifted its holdings in shares of Cybin by 38.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock worth $5,230,000 after acquiring an additional 5,340,000 shares during the period. 17.94% of the stock is owned by institutional investors.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.